Cagrilintide monotherapy for treatment of obesity In a 26-week phase 2 trial (n=706, 62 Percentage women, mean age 52 years), cagrilintide was evaluated in 5 groups of subjects receiving 0.3, 0.6, 1.2, 2.4, and 4.5 mg/week as treatment for obesity in comparison with liraglutide 3.0 mg/day, and placebo (table 1) [9]
Combined with increased urination (a common effect during early weight loss) and potential vomiting during nausea episodes, electrolyte depletion can cause fatigue, headaches, muscle cramps, dizziness, and cognitive fog
Learn about SPF and why it's crucial for your lips on our dedicated blog
This ensures your treatment plan is tailored to your bodys actual needs